Showing results (411-420 of 2,902) with videos related to
Sort By:
Pageof 291
Cancer Gene Therapy|October 8, 2005
Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivoJ Zhao, J Jin, X Zhang, et al.Cancer Gene Therapy|October 8, 2005
Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicinH Ganjavi, M Gee, A Narendran, et al.Cancer Gene Therapy|May 14, 2005
RNA interference and potential therapeutic applications of short interfering RNAsTom C Karagiannis, Assam El-OstaCancer Gene Therapy|May 14, 2005
Gene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agentsYoshikazu Sakakima, Shuji Hayashi, Yoshikazu Yagi, et al.Cancer Gene Therapy|March 5, 2005
A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion proteinMarina Tychopoulos, Laurent Corcos, Philippe Genne, et al.Cancer Gene Therapy|September 24, 2005
Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A regionY Saito, M Sunamura, F Motoi, et al.Cancer Gene Therapy|July 23, 2005
Targeting proliferating tumor cells via the transcriptional control of therapeutic genesI A W Ho, K M Hui, P Y P LamCancer Gene Therapy|August 6, 2005
Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cellsM Yamamoto, N Nishimoto, J Davydova, et al.Cancer Gene Therapy|November 24, 2007
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor modelsS C Cheong, Y Wang, J-H Meng, et al.Cancer Gene Therapy|November 3, 2007
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR)D C Singleton, D Li, S Y Bai, et al.Pageof 291